Specialty Drugs

Why Where You Infuse Biologics Matters: Site-of-Care Optimization for Employer Health Plans

When a $16,400 Remicade Infusion Isn’t Inevitable

One of my longest-tenured clients, a 700-employee food manufacturer, came to me with a spike in their pharmacy trend last spring. Their annual pharmacy spend had jumped from $1.2 million to $1.6 million. Digging into the claims, we found two new Remicade (infliximab) patients. Both received infusions at the local hospital outpatient center. Each session cost over $16,000 in allowed charges, billed through the medical benefit. Had those same infusions occurred at a physician’s office or specialized infusion center, the plan would’ve paid closer to $5,000 per session. For a chronic condition like Crohn’s, that’s a $33,000-per-member annual gap, over $65,000 in avoidable spend for just two employees.

This isn’t rare. If you manage a plan of 500 or more, you’ve seen these claims pop up: $12,000 for an IVIG infusion, $8,500 for Entyvio, $26,000 for the hospital’s “facility fee.” CFOs always ask, “Are we paying the going rate?” The answer is usually no, not if site-of-care isn’t actively managed. With specialty drugs now 50-55% of total pharmacy plan costs (see PBM benchmarks), site-of-care is no longer a niche tactic, it’s mainstream.

What Makes Hospital Outpatient So Expensive for Infusions?

Hospitals have negotiating power with carriers, so their allowed charges, what your plan actually pays, routinely run 2 to 4 times higher than independent physician offices or ambulatory infusion centers. The higher cost isn’t due to a better patient experience or superior safety in most cases. It comes from bundled “facility” and “infusion administration” fees, as well as more aggressive markups on the drug itself. A hospital may bill $10,000 for the drug plus $6,000 for administering it, compared to $3,500 and $800 at a non-hospital clinic.

For the employer, this all comes through medical claims, often invisible to HR and pharmacy stakeholders until stop-loss carriers start asking questions or the plan’s actuary flags a trend spike. What’s worse, fully insured plans often have little insight into these details unless they push their carrier for reports combining medical and pharmacy spend.

Not all drugs or patients are appropriate for a lower-cost site. Acute, high-risk infusions may belong in the hospital. But for a huge range of maintenance therapies, including Remicade, Ocrevus, Entyvio, IVIG, and even some oncology drugs, most patients can safely receive treatment in a physician’s office or a high-quality ambulatory site. Many PBMs and health plans now offer “site-of-care management” programs, but their effectiveness varies widely. Some simply send a letter. Others actively coordinate patient transitions and connect them with nurse case managers.

How Much Can Employers Really Save? Real-World Examples

You’ll see studies quoting “up to 50%” savings. That’s accurate, but the math depends on volume, local market pricing, and how aggressively your plan can steer members. Here’s a real scenario:

  • Employer: 1,200 lives, self-funded, $135 PMPM pharmacy cost, $2.2M annual pharmacy + medical spend on specialty drugs
  • Cohort: 14 patients receiving regular infused specialty drugs, 9 at hospital outpatient, 5 at physician office/infusion center
  • Average cost per infusion (hospital): $13,400
  • Average cost per infusion (non-hospital): $4,900
  • Potential annual savings if 7 of 9 hospital patients move to lower-cost site: about $330,000 (net of patient transportation, new site onboarding)

Those are real numbers, not vendor promises. For a 1,200-life plan, $330,000 is over $22 PMPM in addressable savings, a powerful offset to the runaway growth in GLP-1 and immunology drug costs. Even smaller employers can see five-figure impacts if they have just 2-3 high-utilizer patients.

One caveat: not every patient can be moved, and the transition isn’t frictionless. Patient disruption must be weighed against savings. A good pharmacy benefits consultant will coordinate with your TPA, PBM, and any specialty case management vendor to map out which patients are eligible by diagnosis, treatment history, and proximity to infusion centers. You’ll want clear communications, both for patients and their providers, to avoid missed treatments or dissatisfaction. For more detail on drug pricing differentials, check current rates for top infused drugs.

Steering Patients: Tactics That Actually Work (and What Can Backfire)

Not all site-of-care interventions deliver the same results. Some PBMs and medical TPAs now include automatic site-of-care review in their specialty prior authorization process. That means, when a prescriber requests an infusion, the plan checks whether a lower-cost site is available and appropriate. If so, approval is contingent on moving, unless there’s a clear clinical reason to keep the patient in hospital outpatient.

Still, you need more than a policy on paper. The most effective programs I’ve seen do three things:

  • Pair site-of-care review with white-glove case management, actively helping patients and providers transition to a new infusion site
  • Offer patient support for transportation or scheduling, since location and convenience are big barriers
  • Maintain flexibility for exceptions, some patients simply cannot move, and hard line rules can create member grievances

What doesn’t work? Sending a single letter, then crossing your fingers. Patients often ignore generic notices, and providers may default to their health system’s outpatient center out of habit or financial incentive. Some states also have “any willing provider” or anti-steering laws, which require careful compliance. If you’re self-insured and subject to ERISA, work closely with your ERISA attorney before implementing any mandatory steerage program to avoid accusations of limiting provider access.

It’s also critical to coordinate with stop-loss carriers. Some have their own embedded site-of-care programs or even require attempts at site-of-care optimization before reimbursing catastrophic claims. If your plan is insured, find out if your carrier or PBM has any active interventions, or if you need to request one. Mid-market employers with limited resources may benefit from third-party nurse navigation services or PBM programs that handle patient outreach end-to-end.

For benefits leaders facing rising specialty claims, site-of-care optimization offers a high-impact way to rein in costs, if it’s implemented with clinical nuance and patient support. Some drugs, like Remicade, Rituxan, and IVIG, have 3-4 fold price differentials between settings. Others, like certain new gene therapies or complex oncology regimens, don’t have safe alternatives. You’ll want to check with a pharmacist or medical director for each drug and diagnosis. For drug-specific clinical questions, consult current clinical guidelines and safety data.

What to Watch For: Pitfalls and Practical Next Steps

In the real world, execution is everything. Site-of-care optimization isn’t just a PBM “knob” you turn on. Without clear reporting, you can miss high-cost outliers. Without patient navigation, you invite complaints and possible delayed care. And unless you coordinate with your TPA, PBM, and specialty pharmacy vendor, you’ll risk conflicting messages or even claims denials.

Here’s what I typically recommend to benefits teams looking to tackle infusion site-of-care:

  • Start with a claims data pull (ask for site-of-service, not just diagnosis or drug code) to map current utilization and cost by setting
  • Work with your PBM and TPA to evaluate existing site-of-care management programs, some do much more than others
  • Identify local infusion capacity, rural employers may have limited options, so check before moving forward
  • Bring in a pharmacy benefits consultant if you don’t have in-house clinical staff to review which drugs and patients are eligible for transition
  • Confirm with stop-loss and legal partners (especially if self-funded) before enforcing any steerage rules

If you’re fully insured or have a carve-in pharmacy, pressure your carrier for transparent reporting and find out what site-of-care tactics they actually use, not just what’s in the glossy brochure. For up-to-date specialty drug news and payer policies, track policy shifts and regulatory changes here.

Site-of-care optimization is one of the few specialty drug management strategies that saves real money without restricting clinical access. Handled well, it’s a win for both the plan’s bottom line and for employees who prefer convenient, non-hospital care. Handled poorly, it becomes a source of headaches and HR complaints. The difference is almost always in the details, and in the hands-on support provided to your members and their providers.